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Abstract In 2004, circulating tumor cells (CTC) enumeration
by the CellSearch® technique at baseline and during treatment
was reported to be associated with prognosis in metastatic
breast cancer patients. In 2008, the first evidence of the impact
of CTC detection by this technique on survival of cM0(i+)
patients were reported. These findings were confirmed by
other non-interventional studies, whereas CTC were also in-
vestigated as a surrogate for tumor biology, mainly for HER2
expression/amplification. The aim of this report is to present
the current prospective large interventional studies that have
been specifically designed to demonstrate that CTC enumera-
tion/characterization may improve the management of breast
cancer patients: STIC CTC METABREAST (France) and
Endocrine Therapy Index (USA) assess the CTC-guided
hormone therapy vs chemotherapy decision in M1 patients;
SWOG0500 (USA) and CirCe01 (France) assess the CTC
count changes during treatment in metastatic patients; DE-
TECT III (M1 patients, Germany) and Treat CTC (cM0(i+)
patients, European Organization for Research and Treatment
of Cancer/Breast International Group) assess the use of anti-
HER2 treatments in HER2-negative breast cancer patients
selected on the basis of CTC detection/characterization. These
trials have different designs in various patient populations but
are expected to be the pivotal trials for CTC implementation in
the routine management of breast cancer patients.
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1 Introduction
Circulating tumor cells (CTC) designate cancer cells that are
detected in the blood of cancer patients. Their detection, quan-
tification, and characterization represent a new window on
cancer dissemination and have opened major perspectives for
both biological and clinical research on the metastatic process.
Commonly accepted endpoints in clinical research for both
nonmetastatic and metastatic breast cancer patients are detailed
in Box 1. Technically, as most carcinomas do not have specific
and recurrent DNA mutation or fusion transcripts, CTC isola-
tion methods rely on the detection of cells that express
epithelial-related markers in blood. Since the normal compo-
nents of human whole blood are mesenchymally derived, they
are not identified using this strategy; this principle is similar to
the detection of isolated breast tumor cells in axillary lymph
node in pN0(i+) breast cancer patients. In 2012, the standard for
CTC detection remains the CellSearch® system (Veridex),
which is still the only system that has been approved by the
FDA for in vitro diagnosis purposes. In 2004, a seminal study
with this technique showed that CTC count was an independent
prognostic factor for both progression-free (PFS) and overall
(OS) survival in metastatic (M1) breast cancer patients [1]. In
this report, the threshold of ≥5 CTC/7.5 ml to define the poor
prognosis group was “learned” from a training group (n0102
patients) and validated in another group of patients (n075
patients). This prognostic value for PFS and OS has been
repeatedly validated in smaller following studies [2–4]. Unsur-
prisingly, a pooled analysis confirmed these results in multivar-
iate analysis [5]. A prospective study “IC 2006-04,” specifically
designed and powered to assess the prognostic value of CTC
count changes in patients treated by first-line chemotherapy
(with or without targeted therapy), had the same conclusions
in multivariate analysis and supported the use of the ≥5 CTC/
7.5 ml threshold [6]. Serum markers have been also prospec-
tively assessed [7] and were not prognostic markers in multi-
variate analysis. The only issue appeared with the use of
targeted therapy, namely trastuzumab and bevacizumab, which
decrease profoundly the CTC count: some reports suggested
that this decrease might impact its prognostic value [8, 9].
Moreover, recent data have suggested an adverse prognostic
value of CTC detection in nonmetastatic breast cancer [10–12].
At the same time, HER2 expression on CTCs using the Cell-
Search® system was studied in the neoadjuvant setting [13] and
across all breast cancer stages from preinvasive lesions to overt
metastatic disease [14].
Box 1. Clinical settings and endpoints
     The different trials presented above are using commonly accepted endpoints to judge
whether a treatment or a strategy is clinically relevant. Two settings must be clearly separated; First, 
patients diagnosed with a breast cancer and with no overt metastasis (M0) reported by a clinical and 
radiological screening. In this non-metastatic setting, treatments are intended to cure the patients, 
and include surgery, followed by loco-regional radiotherapy and systemic treatments (hormone 
therapy, chemotherapy, targeted therapy). These adjuvant treatments are made to lower the 
frequency of later metastatic relapse. The most clinically relevant endpoints are therefore the time 
from breast cancer surgery to any relapse (local or distant), called “disease-free survival”, and to 
patient death, called “overall survival” (OS). As the relapse and/or death generally occur many years 
after the primary tumor treatment, it is commonly accepted to use surrogate endpoints. The TREAT 
CTC trial, presented above, will include only M0 patients, and is using as a primary endpoint the rate 
of CTC disappearance after adjuvant treatments, this data being available quickly. Disease-free 
and overall survival will be also studied as secondary endpoints, when they will be available (i.e.
probably 5 to 10 years later).
           The second setting is metastatic (M1) breast cancer. For these patients diagnosed with breast
 cancer metastases, treatments are generally palliative, and aim at extending the patient life without 
deteriorating the patient quality of life. Patients are receiving successive “lines” of treatment. 
Chemotherapy, hormone-therapy and targeted therapy are all assessed similarly, with radiological 
measurement of the diameter of the different metastases. The radiological measurement is 
standardized, following the RECIST guidelines [26]. The sum of the diameters is measured before 
treatment start, and is used for comparison with new radiological exams made at regular intervals, 
every 2 to 3 months. The disappearance (100% diameter shrinkage) of the metastases is called a 
“complete response”, a decrease of more than 30% is called a “partial response”, variations between 
-30% and +20% is a “stable disease”, whereas an increase of more than 20% of the metastases 
diameters or the appearance of a new metastasis is a “progressive disease” – which signs the end of
treatment efficacy, and the start -if possible- of a new line with another treatment. In M1 patients, 
assessing a treatment or strategy efficacy relies therefore mostly on progression-free survival (PFS,
i.e. time from treatment start to tumor progression), tumor response rate (rate of patients experiencing 
a complete and or partial response of their tumor) and overall survival (OS, i.e time from treatment
start to patient death). Most of the trials presented here aim at improving metastatic patients care, 
and used response rate, PFS and /or OS as endpoints. 
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With these numerous non-interventional studies published,
interventional controlled “phase III” trials were needed to
demonstrate that the use of CTC enumeration and monitoring
could improve the outcome of breast cancer patients and/or
lower the medical costs paid by the patient or its insurer. The
aim of this article is to report and discuss the different inter-
ventional trials currently ongoing or on the edge of starting
that have been set up by different CTC research groups in the
world. Basically, CTCs are investigated as prognostic markers
in the STIC CTC METABREAST trial and Endocrine Ther-
apy Index (ETI) study, as early surrogate of chemotherapy
efficacy in the SWOG0500 and in the CirCe01 trials, and
finally as an indicator of tumor biology in the Treat CTC,
DETECT III, and CirCe XXX1 trials.
2 STIC CTC METABREAST (France)
Rationale As stated above, baseline CTC count has unam-
biguously demonstrated its very good performance as an
independent prognostic marker. Multivariate analyses per-
formed in both the pooled analysis and in the IC 2006–2004
study showed that the other independent prognostic factors
were the performance status and hormone receptor (HR)
status. Oppositely, the other criteria that are frequently used
to choose between hormone therapy and chemotherapy for
the treatment of first-line metastatic HR + breast cancer
patients (e.g., metastatic sites, metastasis-free interval…)
were not independent prognostic factors. It has been then
proposed that CTC count may be a better criterion for this
important choice than the currently used empiric criteria,
which have a low level of evidence (expert consensus).
Design In the STIC CTC METABREAST trial (NCT0
1710605), about 1,000 HR + M + breast cancer patients
will be randomized between the clinician choice and CTC
count-driven choice (Fig. 1). In the CTC arm, patients with
≥5 CTC/7.5 ml will receive chemotherapy whereas patients
with <5 CTC/7.5 ml will receive endocrine therapy as first-
line treatment. Within each treatment category (hormone or
chemotherapy), the treatment type will be the clinician
choice, targeted therapy being allowed. The only difference
between CTC and standard arms will be the rates of hor-
mone therapy vs chemotherapy-based treatment. As every
patient will receive a treatment, this pivotal trial has been
designed to show a non-inferiority of the CTC arm for PFS
(primary clinical endpoint) and a superiority of the CTC arm
for the medico-economics study (co-primary endpoint). This
trial began in February 2012. Several secondary endpoints
are pre-planned (subgroups analyses).
Funding The STIC CTC METABREAST trial has been
funded by the French Ministry of Health (STIC program,









Randomization • Stratified on center, PS and metastasis-free interval
• M+ HR+ HER2- patients before any treatment
















• The study will also adress what is the optimal strategy (centralized vs local CTC lab.) from the economical viewpoint
• Primary medical endpoint: PFS (non-inferiority)
• 2nd endpoints: OS, toxicities, QoL, subgroup analyses
• Co-primary economical endpoint: cost/benefit ratio
Fig. 1 The STIC CTC METABREAST trial design
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Alternate proposal Based on the same rationale (standard
criteria for treatment decision between hormone therapy or
chemotherapy may be weaker than CTC count), another
strategy is currently developed that takes into account not
only the number but also the biology of CTC [15, 16]. Four
biological markers are assessed on isolated CTC by immu-
nocytofluorescence in the CellSearch® system: estrogen
receptor, Bcl2, HER2, and Ki67. The global level of expres-
sion per isolated CTC of each marker is determined, and a
score called “Endocrine Therapy Index” is assigned for each
marker for that blood draw, based on both the staining inten-
sity and the proportion of positive CTC. The relative weights
of the criteria (the number of CTC and the expression of each
of the four biomarkers) are used to derive an “ETI score.” An
American pilot study to establish the analytical validity of this
assay is near completion and a larger trial to test the clinical
validity is now being planned.
3 SWOG 0500 (USA)
Rationale As stated above, several observational studies
support the fact that CTC changes during the weeks follow-
ing the first cycle of chemotherapy is associated with PFS
and OS [1]. This observation is intriguing, since other
soluble protein markers often rise before they decline—the
so-called tumor marker spike. This phenomenon makes
assessment of protein biomarkers much less accurate in the
early phases of a new treatment, whereas CTC spikes have
not been observed. Therefore, CTC levels early in the course
of a new therapeutic regimen for metastatic disease appear to
reflect response, whereas lack of reduction of CTC levels
may reflect futility of the respective treatment, thus making
early CTC levels a short-term “predictive” factor. These data
opened a whole new vision of the “personalized medicine” in
metastatic breast cancer as no predictive factor—except HR
and HER2—have been strongly validated in stage IV breast
cancer. In this context, the promise of CTC count was to
evaluate the efficacy of any chemotherapy after only one cycle
and then to switch non-responding patients to another
chemotherapy before the disease progression. However,
the clinical benefit of such revolutionary management—
compared to the standard radiological evaluation—was
unknown. This protocol was the first interventional trial
to be designed to demonstrate that CTC-driven management
of chemotherapy improves the outcome of metastatic breast
cancer patients.
Design The SWOG 0500 (NCT00382018) design is shown
Fig. 2: in the screening part of the trial, metastatic patients
treated by first-line chemotherapy (combined or not with
targeted therapy) had their CTC count determined before
cycles 1 and 2. Patients with persistently elevated CTC (≥5
CTC/7.5 ml) after one cycle (i.e., around days 21–28) are at
higher risk of early cancer progression and were randomized
between continuation of the first-line chemotherapy (until
classic evidence of clinical or radiological progression) or to
early switch to another chemotherapy regimen, before any
radiological progression. The “early second line” and further
treatment lines were managed by the usual clinical–radiological
parameters. Accrual started in 2006 and has been completed in
March 2012: about 610 patients were screened and 120 patients
randomized (source: www.swogstat.org). The primary end-
point of the trial is to demonstrate an improvement in OS in
the CTC-driven arm.
Funding The SWOG 0500 trial has been funded by the
National Cancer Institute of the USA through the South-
West Oncology Group (SWOG), and Veridex supported the
study. The promoter is the SWOG.
4 CirCe01 (France)
Rationale The CirCe01 study is basically another attempt to
demonstrate that patients who received a first cycle of
chemotherapy and whose CTC count did not drop should
be switched off this chemotherapy. Based on the assumption
that CTC count is a test to detect chemoresistance, it was
supposed that this test will perform better in a population
with chemoresistance prevalence, i.e., in the advanced meta-
static setting. Another idea is that, to show a clinical
improvement in the CTC-managed arm, the CTC test
should be repeated more than once in patients. So the
early CTC “go/no go” test will be performed not only
once, but at the beginning of every new chemotherapy
line in patients randomized in the CTC arm (i.e., to
evaluate the third, fourth, fifth… lines). In the CTC
arm, it has been hypothesized that many patients with
chemoresistant tumor will experience repeated early che-
motherapy changes (e.g., three chemotherapy regimens
tested in 9 weeks), giving support to the discontinuation
of inefficient, toxic, and costly chemotherapies and the
start of palliative care. It is believed, for this subgroup
of patients, that such de-escalating management will
benefit both patients and health care systems. For some
other patients, it is also expected that they will benefit
from the early chemotherapy turnaround and find
quicker an efficient therapy among all those tested.
Design The first step of the CirCe01 (NCT01349842) trial
was conducted from March 2010 to October 2011. This
non-interventional step was intended to check the clinical
relevance of the ≥5 CTC/7.5 ml threshold in these heavily
pretreated patients or to propose alternate decision criteria.
The design of the interventional part of the trial, which
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started in February 2012, is shown in Fig. 3: 304 patients with
high CTC count before the start of the third line of chemo-
therapy will be randomized between the CTC-driven arm and
the standard arm. In the CTC-driven arm, CTC counts will be
performed after each first cycle of every new chemotherapy
drug and will indicate whether or not this regimen is worth to
be pursued. Patients with insufficient CTC decrease will be
switched off from this chemotherapy line andwill be eventually
proposed with a further line of treatment, which will be, again,
evaluated by early CTC changes (and so on). Patients with a
significant CTC decrease before the second chemotherapy
cycle will continue their treatment and then managed by stan-
dard clinical/radiological tools (the next chemotherapy line
being again initially evaluated byCTC, and so on). Themedical
primary endpoint of the trial is the overall survival, whereas a
medico-economic study as a co-primary endpoint. Several
secondary endpoints are pre-planned, including progression-
free survival, quality of life, anxiety/depression, and compari-
son with serum markers.
Funding The CirCe01 trial has been funded/supported by La
Ligue Contre Le Cancer (#20 %), the French ministry of Health
(#60%), andVeridex (#20%). The promoter is the Institut Curie.
5 Treat CTC (Europe)
Rationale “Treat CTC” is the first, multicenter international
trial assessing CTC detection as a liquid biopsy to test a new
treatment strategy in breast cancer that is the use of trastu-
zumab in HER2 non-amplified disease. Currently, trastuzu-
mab is administered as part of the standard of care only in
women with HER2-overexpressing/amplified tumors [17].
However, data from subset analyses of the NASBP B-31
and the NCCTG N9831 trials [18, 19] and results of a
single-center phase II study [20] suggest that the benefit
from adjuvant trastuzumab may not be confined to HER2-
amplified tumors. These interesting findings could be explained
by several hypotheses that are not mutually exclusive: (1) lower
levels of HER2 expression may be sufficient for benefit from
trastuzumab, (2) small undetectable populations of HER2-
overexpressing cells may drive benefit from trastuzumab, and
(3) trastuzumab may work through eradication of minimal
residual disease by immune-related mechanisms. In the Treat
CTC trial, we hypothesize that women with HER2-non-
amplified, nonmetastatic breast cancer and detectable CTC(s)





















• Stratified on HER2 status 
& measurable/bone only disease
Randomization
• Primary endpoint: OS (superiority; hypotheses HR=0.59, P=81%)
• 2nd endpoints: PFS, toxicities, …
• Randomization stratified on HER2 status & measurable/bone only disease
• To avoid early treatment discontinuation in the standard arm, patients and clinicians are blinded to the second CTC test
• After clinical progression, pts may continue to subsequent lines of therapy as clinically appropriate.
Fig. 2 The SWOG 0500 trial design
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Design The Treat CTC trial (EudraCT 2009-017485-23)
flowchart is presented in Fig. 4. This is a randomized phase
II trial for patients with HER2-non-amplified primary breast








Randomization • Stratified on center, estrogen receptor status, chemotherapy (adjuvant vs neoadjuvant)





6 x Trastuzumab q3w
C1 C2 C3 C4 C5 C6
• Primary endpoint:CTC detection at week 18
• Secondary endpoint: Recurrence-free survival
• HER2 overexpression on CTCs will also be studied in all patients, but it is not required to enter the study



















• M+ patient starting a 3rd line of chemotherapy (L3)
• PS 0-4
Randomization • Stratified on center, PS and time from L1
Screening 
N~600
• Threshold for « insufficient » CTC decrease has been obtained in a non-randomized preliminary part of the trial
• Primary endpoint: OS (superiority)
• 2nd endpoints: PFS, medico-economic study, toxicities, QoL, anxiety…
Fig. 3 The design of the interventional part of the CirCe01 trial
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adjuvant chemotherapy and surgery. Before randomization, a
central review on both the HER2 status of the primary tumor
and the Cellsearch® CTC images will be performed. Eligible
patients will be randomized in 1:1 ratio to either the trastuzu-
mab or the observation arm. Patients randomized to the tras-
tuzumab arm will receive a total of six injections every
3 weeks (loading dose 8 mg/kg IV and 5 cycles at 6 mg/kg
every 3 weeks). Patients randomized to observation shall be
observed for 18 weeks. The primary endpoint will compare
CTC detection rate at week 18 between the two arms, while
the secondary endpoint will compare recurrence-free interval.
Funding The Treat CTC trial is sponsored by the Euro-
pean Organization for Research and Treatment of Can-
cer (EORTC) and has been funded/supported by Roche
and Veridex. This trial will be conducted under the
Breast International Group umbrella.
6 DETECT III (Germany)
Rationale Patients with a HER2-negative primary tumor
can develop HER2-positive CTC during disease progression
[21, 22]. The question if these patients benefit from a
therapy targeted against HER2 is of particular importance.
Case reports have already indicated that initially HER2-
negative metastatic breast cancer patients with HER2-
positive CTC benefit from trastuzumab-containing therapy
regimens [23]. The DETECT III study is a prospective,
multicenter, randomized, open-label, two-arm phase III
study to compare standard therapy alone versus standard
therapy plus lapatinib in patients with initially HER2-
negative metastatic breast cancer and HER2-positive CTCs
(www.detect-studien.de). The small-molecule lapatinib is an
inhibitor of tyrosine kinase activity of both HER2 and
EGFR [24]. If the DETECT III trial succeeds in proving
efficacy as a HER2 treatment in patients with HER2-
positive CTCs, a new strategy in treating metastatic breast
cancer will be established. The longitudinal analysis of CTC
dynamics during follow-up will give new insights into the
biology of CTC in metastasizing breast cancer.
Design The DETECT III study (EudraCT 2010-024238-46)
started in February 2012. The design of the study is shown in
Fig. 5. During the screening phase of the study, 1,426 patients







Randomization • Stratified on hormone receptor status, lines of chemotherapy, type of palliative treatment,
number of metastases, presence of bone metastases
• M+ HER2- patients before 1st-3rd line
• Planned treatment that have been tested in association with lapatinib:
aromatase inhibitors, taxanes, capecitabine, vinorelbine, 




Planned treatment + lapatinib
Tumor evaluation
untill  progression
Weak staining : HER2- Strong staining : HER2+
• Primary endpoint: PFS (superiority)
• 2nd endpoints: OS, overall response rate, clinical benefit rate, QoL, CTC dynamics, safety & tolerability of lapatinib compliance to 
the study protocol, assessment of pain intensity
• Patients with bone metastasis will also receive denosumab in both arms
Fig. 5 The DETECT III trial design
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lines for metastatic disease will be tested for HER2-positive
CTC. In all patients, the HER2 status of the primary tumor
and, if analyzed, of metastatic lesions has to be negative. At
least one HER2-positive CTC/7.5 ml blood has to be detected in
these patients (immunocytofluorescence). Two hundred twenty-
eight patients meeting the inclusion criteria will be randomized
between two arms receiving standard therapy or standard ther-
apy plus lapatinib. Standard treatment will consist of chemo- or
endocrine therapy that is either approved for the combination
with lapatinib or that has been investigated in clinical trials.
Patients with bone metastases will be treated with denosumab
in both arms. The maximum duration of randomized treatment
period is 12 months; the adjacent follow-up period has an
estimated maximum duration of 24 months. Primary endpoint
of the DETECT III study is progression-free survival; secondary
endpoints are overall survival, overall response rate, clinical
benefit rate, and the dynamic of CTC.
Funding DETECT III is funded by GlaxoSmithKline
(82.5 %), Cephalon (15.5 %), and Pierre Fabre Pharma (2 %).
The promoter is the Heinrich Heine University Düsseldorf.
Alternate proposal Based on the same rationale (HER2
“gain” in CTCs at metastatic stage in HER2-negative primary
breast cancers), an interventional phase II study is planned to
open in winter 2012 in France. The “CirCe XXX1” study
(provisional name) will use the gold standard technique for
HER2 amplification assessment that is HER2/CEP17 ratio
measurement by FISH. In this single-arm study, patients with
HER2-amplified CTCwill receive an anti-HER2 drugwithout
combined chemotherapy; response rate will be the study’s
main endpoint. It has been anticipated that such strategymight
be relevant only in patients with high number of HER2-
amplified CTCs; an original adaptive design (Fig. 6) will
allow isolating which patient population will benefit (i.e., the
“granularity” of the screening procedure).
7 Conclusion
Beyond the future of CTC analysis as a biological tool for
understanding of the metastatic process, the CTC count is
clinically a very promising tool. This new dynamic quantitative
and qualitative test deserves an appropriate scientific develop-
ment in order to be efficient and to further improve the life
expectancy and/or the quality of life of breast cancer patients.
Each of the interventional trials presented above has been
designed using the CellSearch® system, as this system has the
largest background of non-interventional studies published in
the past years. This background allowed the accumulation of
clinical data and hypotheses, of which statistical hypotheses
used for such large studies. Interestingly, these studies are not
CirCe XXX1
7 patients « L » + 7 patients « H » treated by anti-HER2 drug
• M+ HER2- patients before 2nd line






N 3 /14 responses
Efficacy in the
whole population
With 1 response 
in each group
Efficacy in the 
L population
With no response 
in H group
Efficacy in the 
H population
With no response 
in L group
Add 7 patients « L » + 7 patients « H » treated by anti-HER2 drug2nd step (N=14): N 4 /28 responses
Efficacy in the
whole population
With 1 response 
in each group
Efficacy in the 
L population
With no response 
in H group
Efficacy in the 
H population










Fig. 6 The CirCe XXX1 (provisional name) trial design
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part of pre-planned development program and are addressing
different but complementary aspects of the CTC clinical utility
in different parts of the world. For example, a similar test result
with stable intrinsic statistical properties (lack of early CTC
changes during chemotherapy) can be used to reach different
objectives: in SWOG0500, the underlying concept is to inten-
sify the frontline treatment for the few metastatic patients who
are not responding. In contrast, in CirCe01, the underlying
concept is to objectively justify the early discontinuation of
useless chemotherapies for the vast majority of patients who
are in a very palliative setting. It is also expected that the global
accuracy of the CTC changes, used as a test for early chemo-
resistance detection, will vary between these two trials, as
chemoresistance rates are different between the first and the
latest chemotherapy lines.
Another interesting aspect is the different trials proposed
to assess the relevance of CTC detection and characterization
as a “liquid biopsy” to test new treatment strategy using anti-
HER2 drugs: the DETECT III trial uses a classical random-
ized phase III trial design and will answer in a large popula-
tion whether or not lapatinib should be added in a HER2−
breast cancer patients population that has been predefined
before the start of the study: metastatic patients with any
HER2+ CTC by immunocytofluorescence. A very different
approach is lead by the Treat CTC trial, which combines the
prognostic information of CTC in the adjuvant setting (cM0
(i+) patients[25]) and the promise of adjuvant trastuzumab
given to HER2-negative patients in past studies. Interesting-
ly, the adjuvant setting is characterized by low CTC detec-
tion rates and by long follow-up, explaining why this trial is
the only one not using survival as first endpoint. Also, the
HER2 status of CTC is not used as inclusion criteria but will
be registered, leading to possible subgroups analysis of tras-
tuzumab efficacy in this high-risk population.
Finally, these trials represent the first attempts to demon-
strate that CTC testing improve the clinical outcome of
metastatic breast cancer. Each of them proposes a different
original design which may guide the setup of further studies
based on dynamic blood markers.
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